Cargando…

A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yanqiong, Mao, Xia, Chen, Wenjia, Guo, Xiaodong, Yu, Liangxiang, Jiang, Funeng, Wang, Xiaoyue, Li, Weijie, Guo, Qiuyan, Li, Taixian, Lin, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994416/
https://www.ncbi.nlm.nih.gov/pubmed/31982775
http://dx.doi.org/10.1016/j.omtn.2019.12.023
_version_ 1783493184327778304
author Zhang, Yanqiong
Mao, Xia
Chen, Wenjia
Guo, Xiaodong
Yu, Liangxiang
Jiang, Funeng
Wang, Xiaoyue
Li, Weijie
Guo, Qiuyan
Li, Taixian
Lin, Na
author_facet Zhang, Yanqiong
Mao, Xia
Chen, Wenjia
Guo, Xiaodong
Yu, Liangxiang
Jiang, Funeng
Wang, Xiaoyue
Li, Weijie
Guo, Qiuyan
Li, Taixian
Lin, Na
author_sort Zhang, Yanqiong
collection PubMed
description Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP could be used to treat hepatocellular carcinoma (HCC) remains unclear. Herein, a total of 161 FBRP candidate targets against HCC were identified according to the topological importance in the “hepatic fibrosis-cirrhosis-cancer axis-related gene-FBRP putative target” network, and mostly enriched in phosphatidylinositol 3-kinase (PI3K)/AKT/nuclear factor κB (NF-κB) signaling. Experimentally, FBRP inhibited liver fibrosis and prevented the development of neoplastic lesions at the early stages of hepatocarcinogenesis in a diethylnitrosamine-induced rat HCC model. FBRP inhibited tumor cell proliferation, induced tumor-specific cell death, and suppressed tumor progression in HCC rats while preventing the activation of PI3K, AKT and IKΚB proteins, reducing the nuclear accumulation of NFΚB1 protein, and decreasing the downstream expression of proteins. Consistently, FBRP suppressed HCC cell proliferation and induced cell cycle arrest in vitro. Co-treatment of FBRP with PI3K inhibitor exhibited an additive inhibitory effect on PI3K/AKT/NF-κB activation. Collectively, our data showed the potentials of FBRP in hepatic fibrosis microenvironment regulation and tumor prevention, suggesting that FBRP may be a promising candidate drug for reduction of fibrogenesis and prevention of HCC.
format Online
Article
Text
id pubmed-6994416
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-69944162020-02-04 A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation Zhang, Yanqiong Mao, Xia Chen, Wenjia Guo, Xiaodong Yu, Liangxiang Jiang, Funeng Wang, Xiaoyue Li, Weijie Guo, Qiuyan Li, Taixian Lin, Na Mol Ther Nucleic Acids Article Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP could be used to treat hepatocellular carcinoma (HCC) remains unclear. Herein, a total of 161 FBRP candidate targets against HCC were identified according to the topological importance in the “hepatic fibrosis-cirrhosis-cancer axis-related gene-FBRP putative target” network, and mostly enriched in phosphatidylinositol 3-kinase (PI3K)/AKT/nuclear factor κB (NF-κB) signaling. Experimentally, FBRP inhibited liver fibrosis and prevented the development of neoplastic lesions at the early stages of hepatocarcinogenesis in a diethylnitrosamine-induced rat HCC model. FBRP inhibited tumor cell proliferation, induced tumor-specific cell death, and suppressed tumor progression in HCC rats while preventing the activation of PI3K, AKT and IKΚB proteins, reducing the nuclear accumulation of NFΚB1 protein, and decreasing the downstream expression of proteins. Consistently, FBRP suppressed HCC cell proliferation and induced cell cycle arrest in vitro. Co-treatment of FBRP with PI3K inhibitor exhibited an additive inhibitory effect on PI3K/AKT/NF-κB activation. Collectively, our data showed the potentials of FBRP in hepatic fibrosis microenvironment regulation and tumor prevention, suggesting that FBRP may be a promising candidate drug for reduction of fibrogenesis and prevention of HCC. American Society of Gene & Cell Therapy 2020-01-10 /pmc/articles/PMC6994416/ /pubmed/31982775 http://dx.doi.org/10.1016/j.omtn.2019.12.023 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Zhang, Yanqiong
Mao, Xia
Chen, Wenjia
Guo, Xiaodong
Yu, Liangxiang
Jiang, Funeng
Wang, Xiaoyue
Li, Weijie
Guo, Qiuyan
Li, Taixian
Lin, Na
A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title_full A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title_fullStr A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title_full_unstemmed A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title_short A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation
title_sort discovery of clinically approved formula fbrp for repositioning to treat hcc by inhibiting pi3k/akt/nf-κb activation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994416/
https://www.ncbi.nlm.nih.gov/pubmed/31982775
http://dx.doi.org/10.1016/j.omtn.2019.12.023
work_keys_str_mv AT zhangyanqiong adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT maoxia adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT chenwenjia adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT guoxiaodong adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT yuliangxiang adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT jiangfuneng adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT wangxiaoyue adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT liweijie adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT guoqiuyan adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT litaixian adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT linna adiscoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT zhangyanqiong discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT maoxia discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT chenwenjia discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT guoxiaodong discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT yuliangxiang discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT jiangfuneng discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT wangxiaoyue discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT liweijie discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT guoqiuyan discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT litaixian discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation
AT linna discoveryofclinicallyapprovedformulafbrpforrepositioningtotreathccbyinhibitingpi3kaktnfkbactivation